

# BLASORBA<sup>™</sup> BR-350(L)

**Plasmaperfusion Column** 



ASAHI KASEI MEDICAL CO., LTD.

A Pioneer in Blood Purification

# Selective adsorption of bilir from p

## **Indication**


### Liver diseases

(especially effective for Fulminant hepatitis, Postoperative hepatic failure, Primary biliary cirrhosis and Hyperbilirubinemia)

# Features of PLASORBA BR-350(L)

- Selective adsorption of bilirubin and bile acid from plasma.
- No need for the replacement of plasma, minimizing the risk of infection with hepatitis, AIDS, etc.
- Applicable to patients with protein allergy.

### Adsorption rate of plasma components (in vitro)



### Experimental conditions

Perfusion method: One-pass operation with small scale column (1/350)


Sample : Human plasma 2.4L (Equivalent volume)


Flow rate : 20mL/min (Equivalent rate)

Plasma sample was collected at the column outlet point when 2.4L (equivalent volume) plasma was treated.

In-house data

### Changes in bilirubin and bile acid concentration by plasma perfusion (in vitro)





### **Experimental conditions**

Sample : Bovine plasma 2L

(5 units/mL heparin, 20 mg/dL bilirubin and 1000  $\mu$ mol/L bile acid added bovine plasma) Temperature : 37°C


Perfusion rate : 20mL/min

In-house data

# ubin and bile acid lasma for efficient liver support.

### Clinical Course

**▼** Changes of adsorption rate (in vivo)




Patients: n=6

Total treatments: 29 times

First Department of Surgery. Okayama University, Japan

# Circuit Diagram



# **Specifications**

Adsorption Column	Adsorbent	Material	Styrene divinylbenzene copolymer
		Volume	350mL
	Priming Volume		130mL
	Container	Material	Polypropylene
	Weight		600g
	Sterilization		Moist heat
Microparticle Removal Filter	Filter	Material	Polyethylene (coated with ethylene-vinylalcohol copolymer)
		Area	0.07m <sup>2</sup>
	Container	Material	Polyvinyl chloride
	Priming Volume		30mL
	Sterilization		Ethylene oxide

### **Caution**

The PLASORBA BR-350 is intended for the treatment of plasma. Never run whole blood through the PLASORBA BR-350. Thrombocytes cannot pass through the PLASORBA BR-350 and may cause blockage. Do not use the PLASORBA BR-350 with plasma containing a large amount of thrombocytes.

# References

### [Reviews of the product]

- 1) Viggiano et al. A comparison among three different apheretic techniques for treatment of hyperbilirubinemia. J Artif Organs. 21:110-6, 2018.
- 2) Krawczyk et al. Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters. Ann Hepatol. 11:710-4, 2012.
- 3) Adani et al. Selective bilirubin removal by plasma treatment with Plasorba BR-350 for early cholestatic graft dysfunction. Transplant Proc. 39:1904-6, 2007.
- 4) Senf et al. Brilirubin-adsorption in 23 critically ill patients with liver failure. Int J Artif Organs. 27:717-722,2004
- 5) Ryan et al. Multisorbent plasma perfusion in fulminant hepatic failure:effects of duration and frequency of treatment in rats with grade III hepatic coma. Artif Organs. 25:109-118,2001
- 6) Takenaka. Bilirubin adsorbent column for plasma perfusion. Ther Apher. 2:129-133,1998
- 7) Ott et al. Plasma separation and bilirubin adsorption after complicated liver transplanation: a therapeutic approach to excessive hyperbilirubinemia. Transplanation. 65:434-437,1998
- 8) Mertens et al. Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasmaperfusion. Blood Purif. 16:341-348,1998
- 9) Iwai et al. Efficacy of Long-Term Plasma Exchange/Plasma Perfusion in End-Stage Primary Biliary Cirrhosis. Jpn J Apheresis 14:91-92,1995
- Iseki et.al. Plasma adsorption to charcoal and ion-exchange resin for treating postoperative hepatic failure. Hepatogastroenterology.
   42:394-398,1995
- 11) Nakano et al. Therapeutic Plasmapheresis for Removing Bilirubin Fractions in Hyperbilirubinemia. Jpn J Apheresis 13:175-176,1994
- 12) Umimoto et al. Evaluation of Apheresis for the Removal of Bilirubin Franctions Therapeutic Plasmapheresis(X II) 181-183,1993
- 13) Alarabi et al. Treatment of pruritus in cholestatic jaundice by bilirubin-and bile acid-adsorbing resin column plasma perfusion. Scand J Gastroenterol. 27:223-226,1992
- 14) Geiger et al. Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR-350) in critically ill patients with intractable jaundice. Int J Artif Organs. 15:35-39,1992
- 15) Tabei et al. Application of plasma perfusion in hepatic failure. Biomater Cells Immobilization Biotechnol. 19:193-201,1991
- 16) Tsunemi et al. A Case of Drug-Induced Intrahepatic Cholestasis Relieved by Bilirubin Adsorption. Therapeutic Plasmapheresis (X). 180-183,1991
- 17) Sone et al. Assessment of bilirubin clearance capacity of a newly developed ion-exchange adsorption column and its possible use as asupportive therapy in hepatorenal syndrome. J Clin Apher. 5:123-127,1990
- 18) Iwamoto et al. A case of Primary Biliary Cirrhosis Treated with Long-Term Plasma Perfusion with a Charcoal Column and an Anion Exchange Column. Therapeutic Plasmapheresis (IX). 346-348,1990
- 19) Morimoto et al. Plasma adsorption using bilirubin-adsorbent materials as a treatment for patients with hepatic failure. Artif Organs. 13:447-452,1989
- 20) Kanto et al. Clinical Application of Anion-Exchange Resin (BR-Series Column) to the Treatment of Intractable Janudice. Therapeutic Plasmapheresis 93-97, 1987

### Asahi **KASEI**

Manufacturer: ASAHI KASEI MEDICAL CO., LTD.

1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006 Japan TEL: +81-3-6699-3771 FAX: +81-3-6699-3773 www.asahikasei-medical.com

Represented in Europe by: ASAHI KASEI MEDICAL EUROPE GmbH

Herriotstrasse 1, 60528 Frankfurt am Main Germany TEL: +49 (0) 69 66 37 15 00 FAX: +49 (0) 69 6 66 51 93